## **Supporting Information**

AC DNAS

## Mueller and Ahmed 10.1073/pnas.0809818106



**Fig. S1.** Colocalization of LCMV antigen with ER-TR7<sup>+</sup> fibroblast cells in the brain, liver, and kidney 8 days after LCMV CL-13 infection of B6 mice. (Scale bars, 20 μm.)



**Fig. S2.** Characterization of MHC I<sup>-/-</sup> BM chimeras. (A) Representative populations of CD4 and CD8 T cells in the blood and expression of H-2D<sup>b</sup> on these cells in WT or MHC I<sup>-/-</sup> BM chimeric mice after reconstitution with  $5 \times 10^7$  splenocytes and before infection with LCMV CL-13. (*B*) Expression of MHC I<sup>+</sup> on responding tetramer-positive CD8<sup>+</sup> T cells in the spleen 15 days after infection.



Fig. S3. Phenotypic analysis of responding D<sup>b</sup>GP33-specific CD8<sup>+</sup> T cells in the spleen 15 days after infection. WT  $\rightarrow$  WT mice (open histograms) and WT  $\rightarrow$  MHC I<sup>-/-</sup> mice (filled histograms). Data are representative of 2–3 independent experiments.

DN A S



**Fig. S4.** (*A*) Viral titers in the serum and spleen after LCMV CL-13 infection. (*B*) T cell responses in the tissues 6 weeks after infection. Total number of D<sup>b</sup>GP33or D<sup>b</sup>GP276-specific CD8<sup>+</sup> T cells in the spleen, liver, and lungs 41 days after CL-13 infection. (*C*) The frequency of D<sup>b</sup>GP33- or D<sup>b</sup>GP276-specific CD8<sup>+</sup> T cells in the indicated tissues at day 41 after infection, relative to that at day 15. (*D*) The number of GP61-specific CD4<sup>+</sup> T cells producing IFN- $\gamma$  in the indicated tissues 41 days after CL-13 infection. \*, *P* < 0.05; \*\*, *P* < 0.01; error bars represent SEM. Data are representative of 2 independent experiments of 4–10 mice per group.